Maximal Exercise Raised BDNF Even in Coronary Disease and Heart Failure
Serum brain-derived neurotrophic factor behaved in a surprisingly resilient way during symptom-limited exercise testing, rising after maximal effort in patients with coronary artery disease and chronic heart failure as well as in healthy volunteers. The study placed a familiar biomarker in an unfamiliar setting: not at rest in a clinic chair, but under the physiologic strain of a cardiopulmonary exercise test. In that context, BDNF did not collapse in the face of cardiac disease. It increased.
Resting differences were more selective. Patients with CAD had significantly lower serum BDNF than healthy controls, with an adjusted difference of –11.38 ng·ml⁻¹ and a 95% confidence interval from −18.65 to −4.10. By contrast, the comparison between CHF and controls did not reach statistical significance, and no significant difference separated CAD from CHF on the resting measurement alone. Those findings place BDNF in the same conceptual space as other circulating biomarkers that may reflect vascular injury, neurohumoral activation, or impaired systemic reserve, yet do not behave identically across all forms of cardiac disease.
Resting BDNF Was Lowest in Coronary Artery Disease
The pattern at baseline is clinically interesting because it points toward disease specificity rather than a uniform signature of cardiac illness. In CAD, lower resting BDNF may mirror chronic vascular stress, endothelial dysfunction, or altered platelet and peripheral tissue handling of the protein. BDNF is often discussed in neurobiology, but it also reaches into cardiovascular physiology through exercise signaling, metabolic regulation, and tissue repair pathways. When resting concentrations fall in CAD, the signal may be less about a single pathway and more about cumulative physiologic wear.
CHF did not separate from controls with statistical confidence in this cohort, which keeps the interpretation restrained. Heart failure is not a single phenotype, and small studies often capture only part of its biologic variability. A modest sample can miss real differences when patients span different severities, treatment exposures, and comorbidity burdens. Here, the absence of significance should not be confused with proof of equivalence.
The disease signal was present, but only in one direction and only in one group.
A Maximal Test Produced a Parallel BDNF Surge Across Groups
The exercise finding may be the most practically useful part of the study. After maximal CPET, serum BDNF rose by 5.99 ng·ml⁻¹ overall, with a 95% confidence interval from 2.44 to 9.54, and the magnitude of that response did not differ significantly between CAD, CHF, and healthy participants. Group-by-time analysis showed no meaningful interaction, with a _p_ value of .987. In plain clinical terms, the diseased myocardium did not appear to blunt the immediate BDNF response to maximal exertion in this dataset.
That matters because exercise is a biologically active intervention, not just a fitness challenge. Symptom-limited exertion mobilizes skeletal muscle, shifts lactate metabolism, changes autonomic tone, and alters shear stress in the vasculature. Any of those mechanisms could plausibly drive BDNF release or redistribution. Lactate, which the investigators specifically examined as a potential moderator, sits near the center of that pathway because it rises during intense exertion and has been linked in prior physiology work to neurotrophic signaling. Even so, this study did not show a group-specific divergence in the acute response.
The practical bedside implication is narrow but real: maximal exercise can still trigger a measurable BDNF increase in patients with stable CAD or CHF, at least in the population studied here.
Sex, Age, Body Mass Index, and Lactate Did Not Explain the Response
The investigators also explored whether sex, age, body mass index, or lactate altered the BDNF response. The response was independent of sex, and the analysis did not identify a clear moderating effect from those additional factors within the available sample. That negative result is informative rather than empty. It suggests that, within the tested range, the acute BDNF rise after maximal exertion may be more robust than a simple demographic model would predict.
Still, a biomarker study of this size cannot map the full range of inter-individual biology. BDNF is influenced by platelet release, peripheral tissue production, inflammation, fitness status, medication exposure, and sampling timing. A single pre- and post-exercise measurement captures only a slice of that complexity. More detailed kinetic sampling might show whether some patients peak earlier, recover faster, or reach a lower absolute maximum despite a similar net increase.
Small Cohort, Clear Signal, Limited Certainty
Fifteen patients with CHF, 14 with CAD, and 14 healthy controls formed the entire dataset, and all participants were either male or postmenopausal female and were between 40 and 75 years old. That design improves biological comparability in one sense, but it also limits how widely the findings can be extended. The study is best read as a physiologic pilot rather than a definitive clinical biomarker trial.
ELISA-based quantification adds analytic rigor, and the repeated-measures framework is appropriate for the pre- and post-exercise comparison. Even so, small cohort work is vulnerable to chance imbalance, confidence intervals that are still wide, and underpowered subgroup analyses. The CHF cohort in particular may contain enough heterogeneity to dilute a true baseline effect or conceal a differential exercise pattern. The absence of a difference in this setting should not be overinterpreted as biologic sameness across all cardiac phenotypes.
Why BDNF Still Matters in Cardiac Medicine
BDNF is emerging as a prognostic biomarker in cardiovascular disease because it sits at the intersection of vascular health, neuronal signaling, and exercise adaptation. In CAD, lower resting levels may reflect impaired restorative signaling or a more adverse cardiometabolic state. In heart failure, preserved exercise responsiveness suggests that neurotrophic signaling is not necessarily exhausted, even when the disease burden is substantial. That combination makes BDNF an intriguing candidate for future work on exercise prescription, risk stratification, and perhaps response phenotyping.
The next step is not to declare BDNF clinically ready, but to determine whether it tracks outcomes, changes with training, or distinguishes patients who benefit most from rehabilitation. This study offers a biologic foothold, not a practice-changing threshold. The strongest conclusion is also the simplest: maximal exercise increased serum BDNF, and CAD carried a lower resting level than control status, while CHF did not produce a statistically significant resting separation in this sample.